Navigation Links
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Date:9/3/2014

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.  

The live presentation takes place on Wednesday, September 10 at 11:30am ET (8:30am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences Reports Second Quarter 2014 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
3. Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
4. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
5. Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
6. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
8. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
9. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
10. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
11. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is teaming ... STI Technologies Limited to lower diabetes healthcare costs in ... innoviCares card, which is available throughout all provinces and ... will be eligible for additional savings when shopping for ...
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
(Date:5/3/2017)... Pa. , May 3, 2017  West ... in innovative solutions for injectable drug administration, announced ... Scientific Affairs and Technical Services, and Diane ... workshops and offering presentations focused on West,s expertise ... injectable products, as well as providing commentary on ...
Breaking Medicine Technology:
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing ... blog post on insurance options. If a Bay Area patient has to search for ... and money. Visiting an in-network provider for a second opinion can ensure a patient ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: ... the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse ... family moved to NYC when she was three. At six, they moved to Dayton, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success ... appropriate instruments for research and understanding the basic principles that were designed to ... on innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories ...
Breaking Medicine News(10 mins):